Home › Liver Cancer (Hepatocellular Carcinoma) › NCT06184152

CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules

Contrast Ultrasound vs. Abbreviated MRI for Detection of HCC in Patients With Indeterminate Liver Nodules

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Child A or B cirrhosis from any etiology with at least one ILN on 4-phase CT, contrast- enhanced MRI, or contrast enhanced US but without HCC at baseline.
* Adults 18 years old and above

Exclusion Criteria:

* Patients post liver transplantation
* Patients with concurrent or prior HCC (LR-5 or biopsy proven)
* other liver cancer including cholangiocarcinoma
* Patients with any active extra-hepatic malignancy
* Patients with significant comorbidity and limited life expectancy, e.g., stage D congestive heart failure, in whom surveillance is not warranted are also excluded given unlikely clinical benefit
* Patients with contraindication to contrast-enhanced MRI or CEUS, including implanted medical devices that are considered MR unsafe and severe claustrophobia

About the study

The study will be conducted at the following locations:

1. UT Southwestern Medical Center 2. Parkland Health and Hospital System 3. University of Michigan

Investigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound for early-stage HCC detection in patients with indeterminate liver nodules.

What is being tested

• CEUS imaging (diagnostic test)
• aMRI imaging (diagnostic test)

Sponsor: University of Texas Southwestern Medical Center · Participants: 600 · Started: Nov 28, 2023

Contact the study team

• Lisa Quirk, MS/MPH · Phone: 214-645-6179
• Sneha Deodhar, MS · Phone: 214-645-1378

Official record on ClinicalTrials.gov — NCT06184152

Locations in the U.S.

Conditions

• Liver Cancer (Hepatocellular Carcinoma)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.